



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/812,214
Applicant: Pankiewicz *et al.*
Filed: March 29, 2004
TC/A.AU.: 1614
Examiner: Unassigned

Confirmation No.: 3043

Docket No.: 08841.105019 PHA 3 Bicyclic US
Customer No.: 20786
Title: Tetraphosphonate Bicyclic Trisanhydrides

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Information Disclosure Statement

Sir:

The citation of information on the accompanying Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy is enclosed for each of references AN, AS, BD, and BF; the remaining references were cited in the parent case U.S.S.N. 10/008,572 or are U.S. patent documents. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,

Madeline I. Johnston, Esq.
Reg. No. 36,174

Dated: April 7, 2004
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145


The PTO did not receive the following listed items(s) Fake and N/A

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, April 7, 2005

Jennifer A. Williams

3530874_1.DOC



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	10/812,214
Filing Date	March 29, 2004
First Named Inventor	Pankiewicz <i>et al.</i>
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	08841.105019 PHA 3 Bicyclic US

3479601_2.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages / Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	5,227,506	A	Saari <i>et al.</i>	07-13-1993	
	AB	5,278,153	A	Biller	01-11-1994	
	AC	5,318,972	A	Miyasaki <i>et al.</i>	06-07-1994	
	AD	5,442,101	A	Hanhijarvi <i>et al.</i>	08-15-1995	
	AE	5,569,650	A	Watanabe <i>et al.</i>	10-29-1996	
	AF	5,654,285	A	Ingall <i>et al.</i>	08-05-1997	
	AG	5,658,890	A	Pankiewicz <i>et al.</i>	08-19-1997	
	AH	5,700,786	A	Watanabe <i>et al.</i>	12-23-1997	
	AI	5,733,897	A	Naumann <i>et al.</i>	03-31-1998	
	AJ	5,935,947	A	Naumann <i>et al.</i>	08-10-1999	
	AK	6,326,490	B1	Pankiewicz <i>et al.</i>	12-04-2001	
	AL	6,713,623	B2	Pankiewicz <i>et al.</i>	03-30-2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Pas- sages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AM	DE	43 41 161	A1	Zeppezauer	06-06-1995		
	AN	WO	92/17488	A1	Ingall and Cage (Fisons PLC)	10-15-1992		
	AO	WO	94/29331	A1	Sloan-Ketting Inst. Cancer Res.	12-22-1994		
	AP	WO	96/00585	A1	CNRS	01-11-1995		
	AQ	WO	98/15563	A1	Codon Pharmaceuticals Inc.	04-16-1998		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AR	GLONEK, T., <i>et al.</i> , "Full anhydridization of methylenediphosphonic acid and of phosphoric acids by a carbodiimide," <i>Inorg. Chem.</i> , 14 (7);1597-1602 (1975).	
	AS	LESIK, K., <i>et al.</i> , "Synthesis of nonhydrolyzable analogues of thiazole-4-carboxamide and benzamide adenine dinucleotide containing fluorine atom at the C2' of adenine nucleoside: Induction of K562 differentiation and inosine monophosphate dehydrogenase inhibitory activity," <i>J. Med. Chem.</i> , 40(16):2533-2538 (August 1, 1997). Abstract published in <i>Advance ACS Abstracts</i> (American Chemical Society) (July 1, 1997).	

Examiner
SignatureDate Con-
sidered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/812,214
				Filing Date	March 29, 2004
				First Named Inventor	Pankiewicz <i>et al.</i>
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	08841.105019 PHA 3 Bicyclic US

3479601 2.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	LIPKA, <i>et al.</i> , "Synthesis of Methylene-bridged Analogues of Nicoamide Riboside, Nicotinamide Mononucleotide and Nicotinamide Adenine Dinucleotide" <i>Nucleosides and Nucleotides</i> , 15:149-167 (1996).	
	BB	MARQUEZ, V.E., <i>et al.</i> , "Thiazole-4-carboxamide Adenine Dinucleotide (TAD). Analogues Stable to Phosphodiesterase Hydrolysis," <i>J. Med. Chem.</i> , 29(9):1726-1731(Sept. 1986).	
	BC	PANKIEWICZ, K.W., <i>et al.</i> , "Synthesis of methylenebis(phosphonate) analogs of ADP Ribose" <i>Collect. Czech. Chem. Commun.</i> , 61:S92-S95 (September 23, 1996).	
	BD	PANKIEWICZ, K.W., <i>et al.</i> , "The practical synthesis of methylenebisphosphonate analogues of benzamide adenine dinucleotide: Inhibition of human inosine monophosphate dehydrogenase (type I and II)," <i>J. Med. Chem.</i> , 40(8):1287-1291 (April 11, 1997). Abstract published in <i>Advance ACS Abstracts</i> (American Chemical Society) (March 1, 1997).	
	BE	PANKIEWICZ, K.W., <i>et al.</i> , "Efficient synthesis of methylenebis(phosphonate) analogues of P1,P2-disubstituted phyrophosphates of biological interest," <i>J. Am. Chem. Soc.</i> , 119:3691-3695 (April 15, 1997).	
	BF	ZATORSKI, A., <i>et al.</i> , "Chemical synthesis of benzamide adenine dinucleotide: Inhibition of human inosine monophosphate dehydrogenase (type I and II)," <i>J. Med. Chem.</i> , 39(12):2422-2426 (June 7, 1996). Abstract published in <i>Advance ACS Abstracts</i> (American Chemical Society) (May 1, 1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.